Expression profile of CYP1A1 and CYP1B1 enzymes in colon and bladder tumors

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Androutsopoulos, Vasilis P ^a   Spyrou, Ioannis ^b   Ploumidis, Achilles ^c   Papalampros, Alexandros Eystathios ^b   Kyriakakis, Michalis ^a   Delakas, Demetrios ^c   Spandidos, Demetrios A ^a   Tsatsakis, Aristidis M ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; MESSENGER RNA;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER STAGING; CATALYSIS; CLINICAL ARTICLE; COLON TUMOR; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; COLONIC NEOPLASMS; CYTOCHROME P-450 CYP1A1; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS;

EID: 84892688551     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082487     Document Type: Article

References (47)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW et al. (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49: 1374-1403. doi:10.1016/j.ejca.2012.12. 027. PubMed: 23485231.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M et al. (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592. PubMed: 17287242.
3. Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W et al. (2007) Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 69(Suppl 1): 62-79. doi: 10.1016/j.urology.2006.11.018. PubMed: 17280909.
4. Failli A, Legitimo A, Orsini G, Castagna M, Spisni R et al. (2013) Antiproliferative effects of 5-fluorouracil and oxaliplatin in colon cancer cell lines: comparison of three different cytotoxicity assays. J Biol Regul Homeost Agents 27: 275-284. PubMed: 23489708.
5. Nebert DW, Dalton TP (2006) The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 6: 947-960. doi:10.1038/nrc2015. PubMed: 17128211.
6. Shimada T, Fujii-Kuriyama Y (2004) Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci 95: 1-6. doi:10.1111/j.1349-7006.2004.tb03162.x. PubMed: 14720319.
7. Schwarz D, Kisselev P, Ericksen SS, Szklarz GD, Chernogolov A et al. (2004) Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R), 18(S)-epoxyeicosatetraenoic acid. Biochem Pharmacol 67: 1445-1457. doi:10.1016/j.bcp.2003.12.023. PubMed: 15041462.
8. Chiaro CR, Patel RD, Perdew GH (2008) 12.(R) - hydroxy-5(Z),8(Z), 10(E),14(Z)-eicosatetraenoic acid [12(R)-HETE], an arachidonic acid derivative, is an activator of the aryl hydrocarbon receptor. Mol Pharmacol 74: 1649-1656.
9. Rodriguez M, Potter DA (2013) CYP1A1 regulates breast cancer proliferation and survival. Mol Cancer Res. PubMed: 23576571
10. Kasai S, Ishigaki T, Takumi R, Kamimura T, Kikuchi H (2013) Betacatenin signaling induces CYP1A1 expression by disrupting adherens junctions in Caco-2 human colon carcinoma cells. Biochim Biophys Acta 1830: 2509-2516. doi:10.1016/j.bbagen.2012.11.007. PubMed: 23174221.
11. Braeuning A, Köhle C, Buchmann A, Schwarz M (2011) Coordinate regulation of cytochrome P450 1a1 expression in mouse liver by the aryl hydrocarbon receptor and the beta-catenin pathway. Toxicol Sci 122: 16-25. doi:10.1093/toxsci/kfr080. PubMed: 21498875.
12. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF et al. (1997) Tumor specific expression of Cytochrome P450 CYP1B1. Cancer Res 57: 3026-3031. PubMed: 9230218.
13. Leung YK, Lau KM, Mobley J, Jiang Z, Ho SM (2005) Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res 65: 3726-3734. doi:10.1158/0008-5472.CAN-04-3771. PubMed: 15867368.
14. Cheung YL, Kerr AC, McFadyen MCE, Melvin WT, Murray GI (1999) Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumors. Cancer Lett 139: 199-205. doi:10.1016/S0304-3835(99)00045-2. PubMed: 10395179.
15. Spink DC, Spink BC, Cao JQ, DePasquale JA, Pentecost BT et al. (1998) Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 19: 291-298. doi:10.1093/carcin/19.2.291. PubMed: 9498279.
16. Bruno RD, Njar VC (2007) Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem 15: 5047-5060. doi:10.1016/j.bmc.2007.05.046. PubMed: 17544277.
17. Patterson LH, Murray GI (2002) Tumor cytochrome P450 and drug activation. Curr Pharm Des 8: 1335-1347. doi:10.2174/1381612023394502. PubMed: 12052211.
18. Callero MA, Suárez GV, Luzzani G, Itkin B, Nguyen B et al. (2012) Aryl hydrocarbon receptor activation by aminoflavone: new molecular target for renal cancer treatment. Int J Oncol 41: 125-134. PubMed: 22485252.
19. Sheldrake HM, Travica S, Johansson I, Loadman PM, Sutherland M et al. (2013) Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1. J Med Chem 56: 6273-6277. doi:10.1021/jm4000209. PubMed: 23844629.
20. Travica S, Pors K, Loadman PM, Shnyder SD, Johansson I et al. (2013) Colon cancer-specific cytochrome P450 CYP2W1 converts duocarmycin analogues into potent tumor cytotoxins. Clin Cancer Res 12: 27-37.
21. Pors K, Loadman PM, Shnyder SD, Sutherland M, Sheldrake HM et al. (2011) Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity. Chem Commun (Camb) 47: 12062-12064. doi:10.1039/c1cc15638a. PubMed: 22002321.
22. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30: 869-874. doi:10.1124/dmd.30.8. 869.
23. Liehr JG, Ricci MJ (1996) 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci U S A 93: 3294-3296. doi:10.1073/pnas.93.8. 3294. PubMed: 8622931.
24. Androutsopoulos VP, Spandidos DA (2013) The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and p53/p21 upregulation. J Nutr Biochem 24: 496-504. doi:10.1016/j.jnutbio.2012.01.012. PubMed: 22749133.
25. Surichan S, Androutsopoulos VP, Sifakis S, Koutala E, Tsatsakis A et al. (2012) Bioactivation of the citrus flavonoid nobiletin by CYP1 enzymes in MCF7 breast adenocarcinoma cells. Food Chem Toxicol 50: 3320-3328. doi:10.1016/j.fct.2012.06.030. PubMed: 22743247.
26. Yu LJ, Matias J, Scudiero DA, Hite KM, Monks A et al. (2001) P450 expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos 29: 304-312. PubMed: 11181500.
27. McFadyen MC, Breeman S, Payne S, Stirk C, Miller ID et al. (1999) Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem 47: 1457-1464. doi:10.1177/002215549904701111. PubMed: 10544218.
28. McFadyen MC, Cruickshank ME, Miller ID, McLeod HL, Melvin WT et al. (2001) Cytochrome P450 CYP1B1 overexpression in primary and metastatic ovarian cancer. Br J Cancer 85: 242-246. doi:10.1054/bjoc.2001.1907. PubMed: 11461084.
29. McFadyen MC, Melvin WT, Murray GI (2004) Cytochrome P450s: novel options for cancer therapeutics. Mol Cancer Ther 3: 363-371. PubMed: 15026557.
30. Sissung TM, Price DK, Sparreboom A, Figg WD (2006) Pharmacogenetics and regulation of human cytochrome P450 1B1: Implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res 4: 135-150. doi:10.1158/1541-7786.MCR-05-0101. PubMed: 16547151.
31. Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS (1996) Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 24: 899-905. PubMed: 8869826.
32. McFadyen MC, Rooney PH, Melvin WT, Murray GI (2003) Quantitative analysis of the Ah receptor/cytochrome P450 CYP1B1/CYP1A1 signalling pathway. Biochem Pharmacol 65: 1663-1674. doi:10.1016/S0006-2952(03)00111-4. PubMed: 12754102.
33. 453Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol Pharmacol 67: 435-443. PubMed: 15486049.
34. Kisselev P, Schunck WH, Roots I, Schwarz D (2005) Associations of CYP1A1 polymorphisms with differential metabolic activation of 17-β estradiol and estrone. Cancer Res 65: 2972-2978. doi:10.1158/0008-5472.CAN-04-3543. PubMed: 15805301.
35. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Charlotta O et al. (2002) Functional Analysis of Six Different Polymorphic CYP1B1 Enzyme Variants Found in an Ethiopian Population. Mol Pharmacol 61: 586-594.
36. Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT et al. (2005) Cytochrome P450 profile of colorectal cancer: Identification of markers of prognosis. Clin Cancer Res 11: 3758-3765. doi:10.1158/1078-0432.CCR-04-1848. PubMed: 15897573.
37. Gibson P, Gill JH, Khan PA, Seargent JM, Martin SW et al. (2003) Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: Implications for drug development. Mol Cancer Ther 2: 527-534. PubMed: 12813131.
38. Pradhan S, Nagashri MN, Gopinath KS, Kumar A (2011) Expression profiling of CYP1B1 in oral squamous cell carcinoma: counterintuitive downregulation in tumors. PLOS ONE 6: e27914. doi:10.1371/journal.pone.0027914. PubMed: 22114726.
39. Hevir N, Sinkovec J, Rižner TL (2011) Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: Lower levels of CYP1B1 and increased expression of S-COMT. Mol Cell Endocrinol 331: 158-167. doi:10.1016/j.mce.2010.09.011. PubMed: 20887769.
40. Pavek P, Dvorak Z (2008) Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab 9: 129-143. doi:10.2174/ 138920008783571774. PubMed: 18288955.
41. Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP et al. (2006) Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res 66: 1187-1193. PubMed: 17145863.
42. Carnell DM, Smith RE, Daley FM, Barber PR, Hoskin PJ et al. (2004) Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int J Radiat Oncol Biol Phys 58: 500-509. doi:10.1016/j.ijrobp.2003.09.064. PubMed: 14751521.
43. Androutsopoulos V, Arroo RR, Hall JF, Surichan S, Potter GA (2008) Antiproliferative and cytostatic effects of the natural product eupatorin on MDA-MB-468 human breast cancer cells due to CYP1-mediated metabolism. Breast Cancer Res 10: R39. doi:10.1186/bcr2090. PubMed: 18454852.
44. Meng LH, Kohlhagen G, Liao ZY, Antony S, Sausville E et al. (2005) DNA protein cross-links and replication dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells. Cancer Res 65: 5337-5343. doi:10.1158/0008-5472.CAN- 05-0003. PubMed: 15958581.
45. Sutherland M, Gill JH, Loadman PM, Laye JP, Sheldrake HM et al. (2013) Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder. Mol Cancer Ther 12: 27-37. doi:10.1186/1476-4598-12-27. PubMed: 23033491.
46. Liehr JC, Ricci MJ, Jefcoate CR, Hannigan EV, Hokanson JA et al. (1995) 4-hydroxylation of estradiol by human uterine myometrium and myoma microsomes: Implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci of the USA 92: 9220-9224. doi:10.1073/pnas.92.20.9220. PubMed: 7568105.
47. McFadyen MCE, Melvin WT, Murray GI (2004) Cytochrome P450 CYP1B1 activity in renal cell carcinoma. Br J Cancer 91: 966-971. PubMed: 15280921.